The Endless Frontier Labs at NYU Stern Named Prix Galien Winner in the Best Incubator/ Accelerator/ Equity Category
The Endless Frontier Labs (EFL) at NYU Stern was named the Prix Galien winner in the Best Incubator/ Accelerator/ Equity category.
The Prix Galien is an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa. It is overseen by The Galien Foundation, which fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. EFL was recognized with this honor at the 19th annual Prix Galien Awards Gala at the American Museum of Natural History in New York City.
Several EFL alumni startups are seeking to bring pathbreaking inventions to the markets. Three—Seed Therapeutics (pioneering molecular glue degraders for neurodegenerative diseases such as Alzheimer’s), Strand Therapeutics (developing programmable mRNA cancer vaccines), and SFA Therapeutics (advancing microbiome-derived, oral small molecules)—were nominated in the Best Startup category. And GrayMatters Health, an EFL alum, won Best Startup (in 2023) for the first FDA cleared self-neuromodulation therapy for PTSD.
According to Professor Deepak Hegde, EFL Founder and Andrew Hamilton Director, “We built Endless Frontier Labs on a simple idea: world-class science deserves a world-class path to patients. That means rigorous milestones, founder-friendly incentives (no equity, no fees), and an ecosystem that converts uncertainty into progress. This recognition matters because it celebrates what we exist to do: turn science into impact.”
Learn more about this recognition here.
Learn more about The Endless Frontier Labs here.
